KRAS and neoplasm: For example, Morikawa et al. detected PIK3CA-H1047R and KRAS mutations in tumor tissues from patients with clear cell ovarian cancer and successfully matched these alterations to ctDNA, which was longitudinally monitored throughout the study [31].